GKT771 is a potent and highly selective inhibitor of NOX1 which has recently been selected as a preclinical development candidate. Phase 1 studies are planned in the second half of 2017. This adds another drug candidate to our NOX pipeline enabling us to address a range of diseases driven by NOX1-dependent angiogenic and inflammatory processes.